- Home
- DLXY vs BIAF Comparison
DLXY vs BIAF Comparison
Compare DLXY & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLXY
- BIAF
- Stock Information
- Founded
- DLXY 2007
- BIAF 2014
- Country
- DLXY Singapore
- BIAF United States
- Employees
- DLXY N/A
- BIAF N/A
- Industry
- DLXY
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DLXY
- BIAF Health Care
- Exchange
- DLXY Nasdaq
- BIAF Nasdaq
- Market Cap
- DLXY 13.9M
- BIAF 13.0M
- IPO Year
- DLXY 2025
- BIAF 2022
- Fundamental
- Price
- DLXY $1.07
- BIAF $2.45
- Analyst Decision
- DLXY
- BIAF Hold
- Analyst Count
- DLXY 0
- BIAF 1
- Target Price
- DLXY N/A
- BIAF N/A
- AVG Volume (30 Days)
- DLXY 223.3K
- BIAF 3.2M
- Earning Date
- DLXY 11-13-2025
- BIAF 11-14-2025
- Dividend Yield
- DLXY N/A
- BIAF N/A
- EPS Growth
- DLXY N/A
- BIAF N/A
- EPS
- DLXY 0.07
- BIAF N/A
- Revenue
- DLXY $314,916,000.00
- BIAF $7,681,059.00
- Revenue This Year
- DLXY N/A
- BIAF N/A
- Revenue Next Year
- DLXY N/A
- BIAF $20.04
- P/E Ratio
- DLXY $15.61
- BIAF N/A
- Revenue Growth
- DLXY 8.90
- BIAF 4.99
- 52 Week Low
- DLXY $0.64
- BIAF $2.34
- 52 Week High
- DLXY $7.16
- BIAF $46.53
- Technical
- Relative Strength Index (RSI)
- DLXY N/A
- BIAF 46.15
- Support Level
- DLXY N/A
- BIAF $2.43
- Resistance Level
- DLXY N/A
- BIAF $3.50
- Average True Range (ATR)
- DLXY 0.00
- BIAF 0.25
- MACD
- DLXY 0.00
- BIAF -0.07
- Stochastic Oscillator
- DLXY 0.00
- BIAF 8.70
About DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.